Limits...
Epigenetic changes in cancer.

Esteller M - F1000 Biol Rep (2011)

Bottom Line: Interest in epigenetics is now booming in all the biomedical fields.For transformed cells, the arena is also expanding to include the wide spectrum of histone modification changes and the interaction with noncoding RNAs.What lies ahead is even more exciting, with the imminent completion of many human cancer epigenomes that will form the basis of better biomarkers and epigenetic drugs.

View Article: PubMed Central - PubMed

Affiliation: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia Spain.

ABSTRACT
Interest in epigenetics is now booming in all the biomedical fields. Initially, interest was sparked within the field of cancer research with the finding of global DNA hypomethylation events in the 1980s, followed by the CpG island hypermethylation of tumor suppressor genes in the 1990s and the approval of DNA demethylating drugs and histone deactylase inhibitors in the 2000s. For transformed cells, the arena is also expanding to include the wide spectrum of histone modification changes and the interaction with noncoding RNAs. What lies ahead is even more exciting, with the imminent completion of many human cancer epigenomes that will form the basis of better biomarkers and epigenetic drugs.

No MeSH data available.


Related in: MedlinePlus

Cancer and the genome
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3100810&req=5

fig-001: Cancer and the genome

Mentions: Many cancer scientists have gotten aboard the epigenetic bandwagon since new, user-friendly PCR- and sequencing-based technologies have been developed. The list of tumor suppressor genes shown to undergo epigenetic inactivation has consequently grown long in the last few years. And in addition to the candidate-gene approach, array-based techniques have also detected on the order of 300 epigenetically modified genes in cancers, using expression arrays combined with DNA demethylating treatments or direct DNA methylation microarrays [9] (Figure 1).


Epigenetic changes in cancer.

Esteller M - F1000 Biol Rep (2011)

Cancer and the genome
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3100810&req=5

fig-001: Cancer and the genome
Mentions: Many cancer scientists have gotten aboard the epigenetic bandwagon since new, user-friendly PCR- and sequencing-based technologies have been developed. The list of tumor suppressor genes shown to undergo epigenetic inactivation has consequently grown long in the last few years. And in addition to the candidate-gene approach, array-based techniques have also detected on the order of 300 epigenetically modified genes in cancers, using expression arrays combined with DNA demethylating treatments or direct DNA methylation microarrays [9] (Figure 1).

Bottom Line: Interest in epigenetics is now booming in all the biomedical fields.For transformed cells, the arena is also expanding to include the wide spectrum of histone modification changes and the interaction with noncoding RNAs.What lies ahead is even more exciting, with the imminent completion of many human cancer epigenomes that will form the basis of better biomarkers and epigenetic drugs.

View Article: PubMed Central - PubMed

Affiliation: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia Spain.

ABSTRACT
Interest in epigenetics is now booming in all the biomedical fields. Initially, interest was sparked within the field of cancer research with the finding of global DNA hypomethylation events in the 1980s, followed by the CpG island hypermethylation of tumor suppressor genes in the 1990s and the approval of DNA demethylating drugs and histone deactylase inhibitors in the 2000s. For transformed cells, the arena is also expanding to include the wide spectrum of histone modification changes and the interaction with noncoding RNAs. What lies ahead is even more exciting, with the imminent completion of many human cancer epigenomes that will form the basis of better biomarkers and epigenetic drugs.

No MeSH data available.


Related in: MedlinePlus